Biotech Values

[dav1234]

Baird says the weakness in Achillion (ACHN -4.5%) is a buying opportunity , following the announcement of the resignation of its Chief Medical Officer. The firm notes that ACHN is in a "catalyst rich period" with a solid pipeline, and is confident the chief Scientific Officer will be able to assume the CMO's duties without any significant disruption